/

Medtech & Pharma

NIS2 · Manufacturers of Pharmaceuticals and Medical Devices

NIS2 · Pharma & Medical Devices

Cybersecurity for Medical Technology and Pharma

Manufacturers of pharmaceuticals, medical devices, and diagnostics fall under NIS2—and are attractive targets for IP theft, ransomware, and supply chain attacks. We provide a Cyber Risk Assessment as a starting point, along with phishing simulations, awareness training, vulnerability management, and incident response for corporate IT and employees—complete with audit-ready documentation.

THE REALITY

Valuable know-how, tightly scheduled supply chains.

Research data, recipes, and engineering designs are worth cold, hard cash to attackers. At the same time, production and delivery rely on ERP, planning, and email—if the office IT goes down, shipping and customer service come to a standstill as well.

67%

of companies in Germany were demonstrably affected by data theft, espionage, or sabotage in 2026, according to Bitkom—with another 29% suspecting it.

250 employees

or more than €50 million in revenue and a €43 million balance sheet total – from this point on, pharmaceutical manufacturers are considered particularly important entities.

€10 million

Fining framework for essential entities – up to €7 million for important entities such as most medical device manufacturers.

Sources: Bitkom Economic Protection 2026 · BSI Act (Section 28, Section 65, Annex 1 and 2 BSIG).

THE REALITY

Valuable know-how, tightly scheduled supply chains.

Research data, recipes, and engineering designs are worth cold, hard cash to attackers. At the same time, production and delivery rely on ERP, planning, and email—if the office IT goes down, shipping and customer service come to a standstill as well.

67%

of companies in Germany were demonstrably affected by data theft, espionage, or sabotage in 2026, according to Bitkom—with another 29% suspecting it.

250 employees

or more than €50 million in revenue and a €43 million balance sheet total – from this point on, pharmaceutical manufacturers are considered particularly important entities.

€10 million

Fining framework for essential entities – up to €7 million for important entities such as most medical device manufacturers.

Sources: Bitkom Economic Protection 2026 · BSI Act (Section 28, Section 65, Annex 1 and 2 BSIG).

Regulatory context

Pharma and medical technology – two paths to NIS2.

Pharmaceutical manufacturers belong to the health sector with high criticality, while medical device manufacturers generally fall under the manufacturing industry. That determines the category—the obligations are largely the same.

01 · Pharmaceuticals

Annex 1 BSIG - Health Sector

Manufacturers of pharmaceutical products are classified as important entities if they have 50 or more employees or an annual turnover and balance sheet total exceeding €10 million, and as particularly important entities if they have 250 or more employees or an annual turnover exceeding €50 million and a balance sheet total exceeding €43 million. Pharmaceutical research and development is also covered.

02 · Medical Technology

Annex 2 BSIG – Typically an Important Entity

Manufacturers of medical devices and in vitro diagnostics with 50 or more employees, or with an annual turnover and balance sheet total exceeding €10 million, fall under the BSI Act—usually as an important entity. Exception: Manufacturers of products classified as critical during a public health emergency belong to the healthcare sector.

03 · Obligations

Risk Management, Reports, Executive Board

Registration with the BSI, risk management in accordance with Section 30 of the BSIG (BSI Act) including supply chain security, notifications after 24 hours, 72 hours, and one month (Section 32 BSIG), implementation and oversight by executive management (Section 38 BSIG). Product-related obligations under the MDR and IVDR remain unaffected.

Legal sources: Federal Office for Information Security Act (Sections 28, 30, 32, 38, 65, Annexes 1 and 2 BSIG) · Regulation (EU) 2022/123.

Regulatory context

Pharma and medical technology – two paths to NIS2.

Pharmaceutical manufacturers belong to the health sector with high criticality, while medical device manufacturers generally fall under the manufacturing industry. That determines the category—the obligations are largely the same.

01 · Pharmaceuticals

Annex 1 BSIG - Health Sector

Manufacturers of pharmaceutical products are classified as important entities if they have 50 or more employees or an annual turnover and balance sheet total exceeding €10 million, and as particularly important entities if they have 250 or more employees or an annual turnover exceeding €50 million and a balance sheet total exceeding €43 million. Pharmaceutical research and development is also covered.

02 · Medical Technology

Annex 2 BSIG – Typically an Important Entity

Manufacturers of medical devices and in vitro diagnostics with 50 or more employees, or with an annual turnover and balance sheet total exceeding €10 million, fall under the BSI Act—usually as an important entity. Exception: Manufacturers of products classified as critical during a public health emergency belong to the healthcare sector.

03 · Obligations

Risk Management, Reports, Executive Board

Registration with the BSI, risk management in accordance with Section 30 of the BSIG (BSI Act) including supply chain security, notifications after 24 hours, 72 hours, and one month (Section 32 BSIG), implementation and oversight by executive management (Section 38 BSIG). Product-related obligations under the MDR and IVDR remain unaffected.

Legal sources: Federal Office for Information Security Act (Sections 28, 30, 32, 38, 65, Annexes 1 and 2 BSIG) · Regulation (EU) 2022/123.

OUR SOLUTIONS

One starting point, four services – together, your complete security program.

We take care of enterprise IT, employees, and emergency scenarios—starting with a Cyber Risk Assessment that provides a risk profile for the entire company. Process control systems, the validation of GxP systems, and the product safety of your medical devices are not part of our offering; in those areas, we collaborate with your existing partners.

GETTING STARTED · NIS2 & ISO 27001

Cyber Risk Assessment

The risk analysis required by NIS2—fully compatible with your ISO/IEC 27001 ISMS and your customers' requirements: covering ten audit domains, know-how protection, development and service access, as well as the supply chain, without interfering with validated systems. The result is a prioritized roadmap complete with a sign-off template for executive management.

Two pages from the sample Cyber Risk Assessment report by Entropy CS: the top five risks with a risk matrix and the action package roadmap
Two pages from the sample Cyber Risk Assessment report by Entropy CS: the top five risks with a risk matrix and the action package roadmap

Continuous training

Phishing Simulation

Industry-specific lures – fake supplier invoices, official authority mail, regulatory updates, internal data requests. Measurable click and report rates per department, immediately usable as proof for NIS2 and customer audits.

Continuous training

Phishing Simulation

Industry-specific lures – fake supplier invoices, official authority mail, regulatory updates, internal data requests. Measurable click and report rates per department, immediately usable as proof for NIS2 and customer audits.

Employee Resilience

Awareness Training

Core course taking around 20 minutes a year, plus short spotlights – for research, production, quality, sales, and administration. Executive management is included and separately documented in the audit-compliant record.

Employee Resilience

Awareness Training

Core course taking around 20 minutes a year, plus short spotlights – for research, production, quality, sales, and administration. Executive management is included and separately documented in the audit-compliant record.

Know the attack surface

Vulnerability Management

Continuous detection and assessment of vulnerabilities in your corporate IT, prioritized by risk. Active scans only during agreed maintenance windows, complete with remediation tracking and audit-ready reports.

Know the attack surface

Vulnerability Management

Continuous detection and assessment of vulnerabilities in your corporate IT, prioritized by risk. Active scans only during agreed maintenance windows, complete with remediation tracking and audit-ready reports.

IMMEDIATE HELP IN AN EMERGENCY

Incident Response

If it happens anyway: Initial assessment via the incident hotline, containment, preservation of evidence, and analysis of the attack vector, as well as drafts for notifications pursuant to Section 32 of the German Federal Office for Information Security Act (BSIG). Mon–Fri 9 AM–5 PM, initial consultation free of charge.

IMMEDIATE HELP IN AN EMERGENCY

Incident Response

If it happens anyway: Initial assessment via the incident hotline, containment, preservation of evidence, and analysis of the attack vector, as well as drafts for notifications pursuant to Section 32 of the German Federal Office for Information Security Act (BSIG). Mon–Fri 9 AM–5 PM, initial consultation free of charge.

WHY ENTROPY CS

Security for regulated medium-sized businesses.

Many medical technology and pharmaceutical manufacturers are medium-sized enterprises—facing high requirements with small security teams. They need clear priorities, reliable evidence, and a partner who is reachable when it matters most.

Priorities instead of catalogues

We start where the risk is highest - typically with phishing, unpatched access points, and the lack of an incident response plan. Step by step, together with your existing team.

One proof for multiple purposes

Every one of our services generates evidence that you can use for NIS2, ISO 27001, customer audits, and your quality management. Effort spent once, value used multiple times.

Operations take priority

We schedule scanning windows, training sessions, and emergency containment to ensure production and delivery continue smoothly. Cybersecurity is a means to an end, not an end in itself.

Answers for Medical Technology and Pharmaceuticals.

Answers for Medical Technology and Pharmaceuticals.

The questions executives, IT leaders, and quality managers ask us. We address further questions in the free Risk Check.

Which NIS2 category applies to us?

Which NIS2 category applies to us?

Do you take care of the cybersecurity of our medical devices?

Do you take care of the cybersecurity of our medical devices?

Do your measures affect validated systems?

Do your measures affect validated systems?

How do you handle supply chain risks?

How do you handle supply chain risks?

What is the management's liability?

What is the management's liability?

How much does this cost?

How much does this cost?

FREE RISK CHECK

30 minutes. An honest picture of your security posture.

Every conversation starts with a free Risk Check – 30 minutes, no obligation. Afterwards, you will receive a written report outlining your cybersecurity maturity level, risk areas, and immediate actions.

FREE RISK CHECK

30 minutes. An honest picture of your security posture.

Every conversation starts with a free Risk Check – 30 minutes, no obligation. Afterwards, you will receive a written report outlining your cybersecurity maturity level, risk areas, and immediate actions.

FREE RISK CHECK

30 minutes. An honest picture of your security posture.

Every conversation starts with a free Risk Check – 30 minutes, no obligation. Afterwards, you will receive a written report outlining your cybersecurity maturity level, risk areas, and immediate actions.